Literature DB >> 17643815

FANCD2 depletion sensitizes cancer cells repopulation ability in vitro.

Alex Lyakhovich1, Jordi Surralles.   

Abstract

Inactivation of Fanconi anemia/BRCA pathway in some cancers causes increased sensitivity to various drugs used for chemo-therapy. Several approaches have been suggested to artificially disrupt this pathway for better treatment. In our study, we have utilized RNA interference technique to knock-down the expression of FANCD2 and sensitize cancer cells undergoing treatment with DNA damaging agents. For this purpose, we transiently depleted FANCD2 by siRNA in a number of breast, bladder, or liver cancer cell lines and screened for mitomycin C or gamma-irradiation sensitivity changes. We could show that knocking-down FANCD2 gene expression increases sensitivity of cancer cells to mitomycin C and to less extent to gamma-rays. Importantly, this effect strongly correlates to repopulation ability of cancer cells and those cell lines with significant FANCD2 depletion revealed decreased recurrence capacity. In summary, the results we presented show proof of principle that opens new possibilities for further preclinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643815     DOI: 10.1016/j.canlet.2007.06.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.

Authors:  Philip S Rudland; Angela M Platt-Higgins; Lowri M Davies; Suzete de Silva Rudland; James B Wilson; Abdulaziz Aladwani; John H R Winstanley; Dong L Barraclough; Roger Barraclough; Christopher R West; Nigel J Jones
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Expression of FANCD2 in sporadic breast cancer and clinicopathological analysis.

Authors:  Bo Zhang; Ru Chen; Jianhua Lu; Qinfang Shi; Xue Zhang; Jianying Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

Review 3.  The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy.

Authors:  Xiaodi Du; Hongyu Song; Nengxing Shen; Ruiqi Hua; Guangyou Yang
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.